Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer;Análisis de marcadores biológicos en el Proyecto Estratégico de Cáncer de Pulmón CIBERES-RTIC Cáncer-SEPAR

Archivos de Bronconeumologia

Volumn 51, Issue 9, 2015, Pages 462-467

  Monsó, Eduard ^a,b   Montuenga, Luis M ^c,d   Sánchez de Cos, Julio ^b,e   Villena, Cristina ^b  

^a Servei de Pneumologia Hospital Universitari Parc Taulí   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

^e HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

Adenocarcinoma; Biobank; Molecular staging; Non small cell lung cancer; Squamous cell carcinoma

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; DEATH ASSOCIATED PROTEIN KINASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MICRORNA; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; ANAPLASTIC LYMPHOMA KINASE; ROS1 PROTEIN; TKTL1 PROTEIN; TRANSKETOLASE; UNCLASSIFIED DRUG;

APC GENE; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CDH13 GENE; CLINICAL ARTICLE; COHORT ANALYSIS; DAPK GENE; GENE; HUMAN; HUMAN TISSUE; NON SMALL CELL LUNG CANCER; P16 GENE; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; RASSF1A GENE; VALIDATION STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; LUNG PARENCHYMA; MOLECULAR DIAGNOSIS; PREDICTION; PROTEIN FUNCTION; STROMA CELL; CLASSIFICATION; GENETICS; LUNG TUMOR; METHODOLOGY; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RESEARCH DESIGN;

EID: 84940451900     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2015.05.005     Document Type: Article

References (63)

1. Globocan 2012 - Home [Internet; consultado 6 Oct 2014]. Disponible en: http://globocan.iarc.fr/Default.aspx.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013, 63:11-30.
3. Youlden D.R., Cramb S.M., Baade P.D. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2008, 3:819-831.
4. Kratz J.R., Jablons D.M. Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer. 2009, 10:151-157.
5. Subramanian J., Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use. J Natl Cancer Inst. 2010, 102:464-474.
6. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350:2129-2139.
7. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304:1497-1500.
8. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol Off J Am Soc Clin Oncol. 2005, 23:5900-5909.
9. Shepherd F.A., Tsao M-S. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2006, 24:1219-1220. author reply 1220-1.
10. Martin P., Leighl N.B., Tsao M-S., Shepherd F.A. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2013, 8:530-542.
11. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn JMD. 2013, 15:415-453.
12. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009, 27:4232-4235.
13. Kwak E.L., Bang Y.-J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010, 363:1693-1703.
14. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007, 448:561-566.
15. Kratz J.R., He J., Van Den Eeden S.K., Zhu Z.-H., Gao W., Pham P.T., et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012, 379:823-832.
16. Nadal E., Chen G., Gallegos M., Lin L., Ferrer-Torres D., Truini A., et al. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013, 19:6842-6852.
17. Sandoval J., Mendez-Gonzalez J., Nadal E., Chen G., Carmona F.J., Sayols S., et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013, 31:4140-4147.
18. Sánchez de Cos Escuín J., Serra Mitjans M., Hernández Hernández J., Hernández Rodríguez H. Registro del Grupo Cooperativo de Cáncer de Pulmón-II de la Sociedad Española de Neumología y Cirugía Torácica. Estudio descriptivo. Arch Bronconeumol. 2013, 49:462-467.
19. Giroux D.J., Rami-Porta R., Chansky K., Crowley J.J., Groome P.A., Postmus P.E., et al. The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2009, 4:679-683.
20. Goldstraw P. Staging manual in thoracic oncology 2009, RX Press, Orange Park, Florida, USA.
21. Goldstraw P. Updated staging system for lung cancer. Surg Oncol Clin N Am. 2011, 20:655-666.
22. Plataforma Biobanco Pulmonar - Bienvenidos a la PBP [Internet; consultado 6 Oct 2014]. Disponible en: http://biobancopulmonar.ciberes.org/.
23. Villena C., Pozo F., Barberà J.A., Vaquer P., Agusti A. The CIBERES Pulmonary Biobank Consortium: an opportunity for cooperative international respiratory research. Eur Respir J. 2011, 37:204-206. CIBERES Pulmonary Biobank Consortium (PBC).
24. De Jager W., Bourcier K., Rijkers G.T., Prakken B.J., Seyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol. 2009, 10:52.
25. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006, 439:353-357.
26. Shedden K., Taylor J.M.G., Enkemann S.A., Tsao M.-S., Yeatman T.J., Gerald W.L., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008, 14:822-827. Director's Challenge Consortium for the molecular classification of lung adenocarcinoma.
27. Larsen J.E., Pavey S.J., Passmore L.H., Bowman R., Clarke B.E., Hayward N.K., et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis. 2007, 28:760-766.
28. Lee E-S., Son D-S., Kim S-H., Lee J., Jo J., Han J., et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res Off J Am Assoc Cancer Res. 2008, 14:7397-7404.
29. Okayama H., Kohno T., Ishii Y., Shimada Y., Shiraishi K., Iwakawa R., et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012, 72:100-111.
30. Raponi M., Zhang Y., Yu J., Chen G., Lee G., Taylor J.M.G., et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006, 66:7466-7472.
31. Tomida S., Koshikawa K., Yatabe Y., Harano T., Ogura N., Mitsudomi T., et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene. 2004, 23:5360-5370.
32. Valles I., Pajares M.J., Segura V., Guruceaga E., Gomez-Roman J., Blanco D., et al. Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer. PloS One. 2012, 7:e42086.
33. Kloosterman W.P., Plasterk R.H.A. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006, 11:441-450.
34. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6:259-269.
35. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. J Pathol. 2011, 223:102-115.
36. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008, 105:10513-10518.
37. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
38. Nana-Sinkam S.P., Croce C.M. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2013, 93:98-104.
39. Kang S.-M., Lee H.-J. MicroRNAs in human lung cancer. Exp Biol Med (Maywood) 2014, 239:1505-1513.
40. De Atauri P., Benito A., Vizán P., Zanuy M., Mangues R., Marín S., et al. Carbon metabolism and the sign of control coefficients in metabolic adaptations underlying K-ras transformation. Biochim Biophys Acta. 2011, 1807:746-754.
41. Jiang P., Du W., Yang X. A critical role of glucose-6-phosphate dehydrogenase in TAp73-mediated cell proliferation. Cell Cycle Georget Tex. 2013, 12:3720-3726.
42. Mitsuishi Y., Taguchi K., Kawatani Y., Shibata T., Nukiwa T., Aburatani H., et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012, 22:66-79.
43. Földi M., Stickeler E., Bau L., Kretz O., Watermann D., Gitsch G., et al. Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep. 2007, 17:841-845.
44. Martín-Bernabé A., Cortés R., Lehmann S.G., Seve M., Cascante M., Bourgoin-Voillard S. Quantitative proteomic approach to understand metabolic adaptation in non-small cell lung cancer. J Proteome Res. 2014, 13:4695-4704.
45. Lee S.J., Lee J., Park Y.S., Lee C.-H., Lee S.-M., Yim J.-J., et al. Impact of chronic obstructive pulmonary disease on the mortality of patients with non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2014, 9:812-817.
46. Shin J.I., Brusselle G.G. Mechanistic links between COPD and lung cancer: a role of microRNA let-7?. Nat Rev Cancer 2014, 14:70.
47. Ayala G., Tuxhorn J.A., Wheeler T.M., Frolov A., Scardino P.T., Ohori M., et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2003, 9:4792-4801.
48. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006, 6:392-401.
49. Wojdacz T.K., Dobrovic A., Hansen L.L. Methylation-sensitive high-resolution melting. Nat Protoc. 2008, 3:1903-1908.
50. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E., et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998, 95:11891-11896.
51. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008, 358:1118-1128.
52. Buckingham L., Penfield Faber L., Kim A., Liptay M., Barger C., Basu S., et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 2010, 126:1630-1639.
53. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 2002, 420:860-867.
54. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008, 454:436-444.
55. O'Dowd C., McRae L.A., McMillan D.C., Kirk A., Milroy R. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010, 5:988-992.
56. Dos Santos Silva I., de Stavola B.L., Pizzi C., Meade T.W. Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol. 2010, 39:699-709.
57. Pine S.R., Mechanic L.E., Enewold L., Chaturvedi A.K., Katki H.A., Zheng Y-L., et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011, 103:1112-1122.
58. Wang R., Lu M., Zhang J., Chen S., Luo X., Qin Y., et al. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res CR. 2011, 30:62.
59. Dougan M., Li D., Neuberg D., Mihm M., Googe P., Wong K.-K., et al. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest. 2011, 121:2436-2446.
60. Hofmann J.N., Yu K., Bagni R.K., Lan Q., Rothman N., Purdue M.P. Intra-individual variability over time in serum cytokine levels among participants in the prostate, lung, colorectal, and ovarian cancer screening Trial. Cytokine. 2011, 56:145-148.
61. Yuan J-M. Green tea and prevention of esophageal and lung cancers. Mol Nutr Food Res. 2011, 55:886-904.
62. Tsukioka T., Nishiyama N., Iwata T., Nagano K., Tei K., Suehiro S. Preoperative serum oxidative stress marker as a strong indicator of nodal involvement in clinical stage I lung adenocarcinoma. Int J Clin Oncol. 2012, 17:250-255.
63. Crohns M., Saarelainen S., Kankaanranta H., Moilanen E., Alho H., Kellokumpu-Lehtinen P. Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy. Free Radic Res. 2009, 43:646-657.